acute myeloid leukemia

[Blood Advances] Scientists studied iron metabolism in patients with acute myeloid leukemia at diagnosis and explored the mechanisms involved using the syngeneic MLL-AF9–induced AML mouse model.

[Biosight Ltd. (Globe Newswire)] Biosight Ltd. announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome or acute myeloid leukemia.

[Blood Cancer Journal] The authors found that interleukin-10 receptor (IL-10R) was overexpressed in most acute myeloid luekemia cells, and played an important role in promoting the stemness of leukemia cells.

[Leukemia] The increased stemness of acute myeloid leukemia (AML) cells promoted by Tregs was verified in vitro and in vivo, and researchers found that blocking the interaction between Tregs and AML cells may be a new approach to target leukemia stem cells in AML treatment.

[Nature Communications] Exploiting the mutational footprint of some chemotherapies, researchers explored their influence on the evolution of hematopoietic cells.

[Trillium Therapeutics, Inc.] Trillium Therapeutics, Inc. announced that it has dosed the first TP53-mutated acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.